Japan Medical Dynamic Marketing, Inc. · TSE:7600

Japan Medical Dynamic Marketing — FY2024 Earnings Presentation

24 slides from Japan Medical Dynamic Marketing's earnings presentation, May 14, 2024

  1. Slide 1: Financial Results Briefing for the Fiscal Year Ending March 2024

    Financial Results Briefing for the Fiscal Year Ending March 2024 May 14, 2024 Representative Director and President Toshiyuki Hironaka TSE Prime Market Securities code：7600 Copyright © Japan Medical Dynamic Marketing, INC. All Rights Reserved.

  2. Slide 2: Agenda

    -Agenda- Results for the Fiscal Year Ended Forecast for the Fiscal Year Ending 1 P. 3 ２ P.18 March 31, 2024 March 31, 2025 - Consolidated Net Sales P. 4 - Key Assumptions P.19 - Consolidated Income Statement P. 5 - Consolidated Income Statement P.20 Prior Year Operating Income - Comparison Analysis

  3. Slide 3: Results for the fiscal year ended March 31, 2024

    Results for the fiscal year ended March 31, 2024 TSE Prime Market Securities code：7600 3

  4. Slide 4: Consolidated Net Sales

    FYE Mar. 2024 Results Consolidated Net Sales （Unit : Millions of yen） ¥23,177M Three Consecutive Years with Record Sales 25,000 vs 23/3 +8.8% 20,000 13,004M yen（+5.2％） 15,000 10,163M yen（+13.7％） 10,000 Average exchange rate for the period: 144.41円/US＄ 5,000 0 20/3 21/3 22/3 23/3 24/3 4

  5. Slide 5: Consolidated Income Statement

    FYE Mar. 2024 Results Consolidated Income Statement FY2024 YoY change FY2023 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results Results sales change change sales Net sales 23,177 100.0 +1,869 +8.8 21,307 100.0 Cost of sales 8,415 36.3 +1,100 +15.0 7,315 34.3 SG&A 13,015 56.2 +

  6. Slide 6: Prior Year Operating Profit Comparison Analysis

    FYE Mar. 2024 Results Prior Year Operating Profit Comparison Analysis Operating The impact of yen depreciation on ODEV product purchases and ODEV SG&A Profit expenses (-280M¥) and higher SG&A expenses (-570M¥) were not offset by higher -277M¥ gross profit (+570M¥) due to higher sales. FYE Mar. 2023

  7. Slide 7: Consolidated Sales by Major Products

    FYE Mar. 2024 Results Consolidated Sales by Major Products FY2024 YoY change FY2023 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results sales change change Results sales Japan 13,004 56.1 +647 +5.2 12,356 58.0 Joint 4,932 21.3 +194 +4.1 4,738 22.2 Trauma 4,563 19.7 +240 +5.6 4,

  8. Slide 8: Japanese Market

    Japanese Market 8

  9. Slide 9: Total Sales in Japan

    FYE Mar. 2024 Results Total Sales in Japan （Unit : Millions of yen） 【After sales deductions】 Review 15,000 13,004M yen  Sales for the full year grew positively (+5.2%) due to an increase in the number of cases acquired in vs 23/3 ＋5.2% all therapeutic fields, despite the impact of reimbursement pri

  10. Slide 10: Sales in Japan – Joint Replacement

    FYE Mar. 2024 Results Sales in Japan – Joint Replacement （Unit : Millions of yen） 【Before sales deductions】 Review 4,932M yen Artificial Hip Joints  THA (Total Hip Arthroplasty): Strong vs 23/3 ＋4.1% 6,000 “Entrada Hip Stem” and the new “Promontory Hip Stem” ➡ Increased number of cases acquired ODE

  11. Slide 11: Sales in Japan - Trauma

    FYE Mar. 2024 Results Sales in Japan - Trauma （Unit : Millions of yen） 【Before sales deductions】 Review 4,563M yen  “PHS” (own brand (ODEV) product) and “ASULOCK” (third- party product), products for treatment of femoral 5,000 vs 23/3 ＋5.6% neck fractures, with double-digit growth ODEV Products Oth

  12. Slide 12: Sales in Japan - Spine

    FYE Mar. 2024 Results Sales in Japan - Spine （Unit : Millions of yen） 【Before sales deductions】 Review 4,000 3,322M yen   “Lince Plate”*(third party product): steady New “Lince α Plate”* (third party product): favorable vs 23/3 ＋4.3%  “Vusion Ti 3D cage”; New “Vusion ARC cage”: growth  “KMC Ball

  13. Slide 13: U.S. Market

    U.S. 米国市場 Market 13

  14. Slide 14: Total U.S. Sales

    FYE Mar. 2024 Results Total U.S. Sales $70.4M Review （Unit ： Million of dollars）  Record sales (US$ basis) 80 vs 23/3 ＋６.2%  Increased customer base 70 contributed to growth 60 ODEV’s exhibition booth at AAHKS 2023 (American Association of Hip and Knee Surgeons Conference) 50 40 30 20 10 0 20/3 21

  15. Slide 15: U.S. Sales – Knee Joint Replacement

    FYE Mar. 2024 Results U.S. Sales – Knee Joint Replacement （Unit ： Million of dollars） $47.4M  Review “BKS TriMax” , “BKS Revision Knee”: ➡ Maintaining Strong Growth 50 vs 23/3 ＋10.7%  Introduction of surgical support systems Enabling Technologies Introduction Naviswiss Navigation System 40 “Navisw

  16. Slide 16: U.S. Sales – Hip Joint Replacement

    FYE Mar. 2024 Results U.S. Sales – Hip Joint Replacement Review （Unit ： Million of dollars） $22.7M   Entrada Hip Stem, Alpine Hip Stem ➡ Double-digit growth. Ovation Tribute Stem ➡ Decrease in the number of 30 vs 23/3 ▲1.8% cases Existing users of our “M/L taper” type hip stems (Ovation/Tribute) h

  17. Slide 17: Sustainability Initiatives (FY2024)

    Sustainability Sustainability Initiatives (FY2024) We enhance financial value as well as non-financial value through ESG activities. Reduction of Respect for Human Improve patient QOL Environmental Impact Rights GHG emissions reduction (Scope 1 + Product development to improve patient Scope 2): 18.3

  18. Slide 18: Forecast for the fiscal year ending March 31, 2025

    Forecast for the fiscal year ending March 31, 2025 TSE Prime Market Securities code：7600 18

  19. Slide 19: Key Assumptions

    FYE Mar. 2025 Forecasts Key Assumptions Assumptions for the Forecast of Full-Year Results for the FYE 2025 Exchange Rate Reimbursement Price Exchange Rate（US＄） Fluctuation Impact Reductions Reimbursement price For every ¥/US$ weakening, reductions of approx. 0.3%. Assumed exchange rate the Impact on

  20. Slide 20: 2025 Forecasts Consolidated Income Statement

    FYE Mar. 2025 Forecasts Consolidated Income Statement FY2025 YoY change FY2024 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Results sales change change sales Net sales 25,200 100.0 +2,022 +8.7 23,177 100.0 Cost of sales 9,150 36.3 +734 +8.7 8,415 36.3 SG&A 14,200 56.3 +

  21. Slide 21: 2025 Forecasts Consolidated Sales by Major Products

    FYE Mar. 2025 Forecasts Consolidated Sales by Major Products FY2025 YoY change FY2024 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast sales change change Results sales Japan 13,500 53.6 +495 +3.8 13,004 56.1 Joint 5,060 20.1 +127 +2.6 4,932 21.3 Trauma 4,670 18.5 +106 +2.3

  22. Slide 22: Main initiatives for the FY2025 (53rd fiscal year)

    FYE Mar. 2025 Forecasts Main initiatives for the FY2025 (53rd fiscal year) Area Details of Initiatives  Product Portfolio Review. Development  Accelerate new product development to expand product lineup.  Reduction of manufacturing costs by strengthening in-house manufacturing capacity.  Cost re

  23. Slide 23: Changes in Capital Expenditures, etc.

    FYE Mar. 2025 Forecasts Changes in Capital Expenditures, etc. FYE Mar. FYE Mar. FYE Mar. FYE Mar. FYE Mar. FYE Mar. （Unit: Millions of yen） 2020 2021 2022 2023 2024 2025 Results Results Results Results Results Forecast Investment in plant and equipment 1,812 1,586 1,665 1,317 1,916 2,030 Depreciatio

  24. Slide 24: Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices

    Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing, INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/ Notes The forward-looking statements in this document are based on information currently

Japan Medical Dynamic Marketing — FY2024 Earnings Presentation on 6ix